Mohamad Mohty
#107,896
Most Influential Person Now
Researcher
Mohamad Mohty's AcademicInfluence.com Rankings
Mohamad Mohtybiology Degrees
Biology
#5782
World Rank
#8347
Historical Rank
Cell Biology
#165
World Rank
#172
Historical Rank
Immunology
#289
World Rank
#300
Historical Rank
Molecular Biology
#555
World Rank
#568
Historical Rank
Download Badge
Biology
Mohamad Mohty's Degrees
- Bachelors Biology Université Paris Cité
- Masters Genetics Université Paris Cité
Similar Degrees You Can Earn
Why Is Mohamad Mohty Influential?
(Suggest an Edit or Addition)Mohamad Mohty's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (2010) (523)
- Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond (2007) (483)
- Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. (2010) (399)
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach (2012) (363)
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. (2019) (346)
- One million haemopoietic stem-cell transplants: a retrospective observational study. (2015) (316)
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. (2008) (307)
- Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. (2011) (298)
- Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. (2008) (290)
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (2020) (283)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
- Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. (2012) (252)
- Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. (2009) (247)
- Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. (2012) (247)
- The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies (2019) (245)
- Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. (2010) (225)
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (209)
- Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. (2009) (201)
- Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia (2012) (198)
- Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
- Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. (2020) (193)
- IFN-α Skews Monocyte Differentiation into Toll-Like Receptor 7-Expressing Dendritic Cells with Potent Functional Activities1 (2003) (192)
- Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission (2016) (189)
- Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. (2003) (187)
- Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. (2002) (186)
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 (2019) (181)
- CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. (2013) (181)
- Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia (2015) (181)
- Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (2019) (177)
- Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. (2001) (174)
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations (2010) (164)
- Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. (2014) (162)
- Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation (2012) (153)
- The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. (2007) (151)
- COVID-19 outcomes in patients with hematologic disease (2020) (144)
- Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors (2019) (141)
- Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update (2011) (141)
- The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation (2018) (141)
- Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center (2004) (134)
- Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. (2004) (134)
- Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation (2014) (132)
- Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. (2009) (131)
- Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report (2018) (128)
- Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. (2011) (128)
- Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years (2021) (127)
- Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. (2009) (125)
- Current status of autologous stem cell transplantation for multiple myeloma (2019) (125)
- Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation (2003) (124)
- Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpl (2016) (122)
- The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies (2019) (120)
- Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia (2011) (118)
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies (2020) (117)
- Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria (2012) (117)
- Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide (2018) (117)
- High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation (2000) (116)
- Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (2015) (115)
- The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy (2020) (115)
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia (2016) (113)
- Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen (2003) (112)
- The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus (2020) (111)
- Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study (2016) (111)
- Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT (2018) (110)
- Acute lymphoblastic leukaemia (2020) (110)
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions (2020) (109)
- Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. (2015) (109)
- Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation (2008) (108)
- Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (2019) (107)
- Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. (2019) (107)
- Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. (2008) (107)
- Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2017) (105)
- Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and (2013) (105)
- The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison (2005) (105)
- Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. (2016) (103)
- Use of Mesenchymal Stem Cells (MSC) in Chronic Inflammatory Fistulizing and Fibrotic Diseases: a Comprehensive Review (2013) (103)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. (2010) (102)
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (2015) (100)
- Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. (2008) (99)
- Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia (2016) (99)
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells (2010) (99)
- Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant (2017) (98)
- Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. (2015) (97)
- Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. (2007) (97)
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study (2011) (97)
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (95)
- Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marr (2012) (95)
- Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group (2010) (94)
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? (2015) (94)
- Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. (2015) (92)
- Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings (2013) (92)
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial (2019) (92)
- Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. (2015) (90)
- Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia (2017) (90)
- Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for (2018) (90)
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial (2021) (89)
- Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials (2007) (86)
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. (2015) (86)
- Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (85)
- Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies (2021) (85)
- Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT (2014) (85)
- Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. (2016) (85)
- The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. (2020) (85)
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. (2015) (85)
- VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. (2007) (84)
- Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2016) (84)
- Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. (2008) (83)
- The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation (2019) (82)
- Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire (2010) (82)
- Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. (2010) (82)
- Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. (2019) (82)
- Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (82)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect (2013) (79)
- Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis (2014) (78)
- Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. (2007) (78)
- Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. (2019) (78)
- Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. (2018) (78)
- Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. (2008) (77)
- Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. (2016) (76)
- Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse (2018) (75)
- Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. (2019) (75)
- Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria (2019) (75)
- Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. (2010) (74)
- Relapsed refractory multiple myeloma: a comprehensive overview (2019) (74)
- VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. (2006) (74)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. (2005) (74)
- G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease (2015) (74)
- The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. (2018) (73)
- Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. (2013) (73)
- Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source (2010) (73)
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (72)
- A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia (2014) (72)
- Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? (2016) (71)
- Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (71)
- Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT (2015) (71)
- A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia (2017) (71)
- [Allogeneic hematopoietic stem cell transplantation]. (2008) (70)
- The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation (2011) (70)
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
- Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2018) (69)
- Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (69)
- Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. (2017) (69)
- Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation (2004) (69)
- Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (2013) (68)
- Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation (2013) (67)
- Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (67)
- Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (2011) (66)
- Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation (2011) (65)
- Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). (2012) (65)
- Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission (2014) (65)
- Unrelated Cord Blood Transplantation: Outcomes After Single-Unit Intrabone Injection Compared With Double-Unit Intravenous Injection in Patients With Hematological Malignancies (2013) (64)
- Rituximab as salvage therapy for refractory chronic GVHD (2008) (64)
- Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis (2002) (64)
- Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma (2008) (63)
- All‐trans retinoic acid skews monocyte differentiationinto interleukin‐12‐secreting dendritic‐like cells (2003) (63)
- Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. (2016) (63)
- Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review (2012) (62)
- European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization (2012) (62)
- Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT (2018) (61)
- Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. (2012) (61)
- Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. (2004) (61)
- Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP (2014) (61)
- Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients (2015) (60)
- High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma (2008) (60)
- Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (59)
- Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. (2014) (59)
- How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. (2020) (58)
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study (2016) (58)
- 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study (2016) (58)
- Adoptive transfer of pp 65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation (2010) (57)
- Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities (2019) (57)
- Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel (2020) (57)
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
- Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. (2016) (57)
- In and out of the niche: perspectives in mobilization of hematopoietic stem cells. (2011) (56)
- Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation (2005) (56)
- Introduction to host microbiome symbiosis in health and disease (2020) (56)
- 25 Years and New Frontiers in Solid Organ Transplantation and Haematology (2011) (56)
- High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation (2007) (56)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (56)
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials (2020) (56)
- Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (2020) (56)
- Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. (2008) (55)
- Long-term physiological side effects after allogeneic bone marrow transplantation. (2010) (55)
- Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT (2016) (55)
- Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers (2014) (55)
- Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT (2018) (55)
- Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first‐line treatment (2005) (54)
- Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT (2016) (54)
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2018) (54)
- Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT (2014) (53)
- New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity (2014) (53)
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome (2019) (53)
- The effects of bortezomib on bone disease in patients with multiple myeloma (2014) (53)
- Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
- How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? (2019) (51)
- Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib (2019) (51)
- Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. (2011) (51)
- Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia (2017) (51)
- Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38– primitive haematopoietic progenitors (2002) (51)
- Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia (2002) (49)
- Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial (2013) (49)
- Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis (2012) (49)
- Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. (2018) (49)
- Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Mal (2015) (49)
- Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial (2020) (49)
- Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood (2014) (49)
- Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison (2009) (48)
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. (2018) (48)
- Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. (2012) (47)
- Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. (2014) (47)
- Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts (2002) (46)
- Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation (2018) (46)
- Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies (2015) (45)
- Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT (2019) (45)
- Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease (2012) (45)
- Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects (2015) (45)
- Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. (2016) (45)
- Sexual health in hematopoietic stem cell transplant recipients (2015) (45)
- Increased Th17/Treg ratio in chronic liver GVHD (2014) (44)
- Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study (2019) (44)
- OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. (2019) (44)
- Effects of bortezomib on the immune system: a focus on immune regulation. (2013) (44)
- Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies (2009) (44)
- Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study (2019) (44)
- Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group (2019) (44)
- Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. (2012) (43)
- A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial (2018) (43)
- Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. (2015) (43)
- Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT (2015) (42)
- Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia (2017) (42)
- Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases (2020) (42)
- Rabbit Antithymocyte Globulin (Thymoglobulin®) (2010) (42)
- Autologous transplant remains the preferred therapy for relapsed APL in CR2 (2016) (42)
- Recovery of Lymphocyte and Dendritic Cell Subsets Following Reduced Intensity Allogeneic Bone Marrow Transplantation (2002) (42)
- Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. (2018) (42)
- “Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries” (2019) (42)
- Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years (2015) (42)
- CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives (2019) (41)
- Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT (2019) (41)
- Inhibition of FLT3 in AML: a focus on sorafenib (2017) (41)
- Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT (2018) (41)
- Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT (2020) (41)
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials (2020) (41)
- Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT (2011) (40)
- Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy (2001) (40)
- Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database (2016) (40)
- Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party (2019) (40)
- Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT (2016) (40)
- Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. (2021) (40)
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
- Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation (2016) (39)
- Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT (2011) (39)
- Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France (2014) (39)
- Machine learning and artificial intelligence in haematology (2020) (39)
- Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT (2016) (39)
- Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2015) (39)
- Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs (2012) (39)
- Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. (2015) (38)
- Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia (2017) (38)
- Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. (2010) (38)
- Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2013) (38)
- Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide (2018) (38)
- Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy (2013) (37)
- Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC) (2005) (37)
- Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine (2018) (37)
- The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. (2017) (37)
- Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2017) (37)
- Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. (2008) (37)
- Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML) (2015) (37)
- Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease (2017) (37)
- Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT (2019) (37)
- Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. (2009) (37)
- Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission (2018) (36)
- Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. (2018) (36)
- Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. (2011) (36)
- Posttransplant maintenance therapy in multiple myeloma: the changing landscape (2017) (36)
- Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. (2006) (36)
- Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation (2004) (36)
- Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen (2004) (36)
- Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022 (2022) (35)
- Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. (2011) (35)
- Impact of valproic acid on dendritic cells function. (2012) (35)
- Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. (2018) (35)
- Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. (2021) (35)
- Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (35)
- Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. (2016) (35)
- Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients (2012) (35)
- Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) (2014) (34)
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma (2019) (34)
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. (2021) (34)
- CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. (2004) (34)
- Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Commi (2020) (34)
- Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. (2008) (34)
- Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. (2014) (34)
- Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. (2017) (34)
- Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10 (2015) (34)
- Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (33)
- Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. (2012) (33)
- Management of patients with multiple myeloma during the COVID-19 pandemic (2020) (33)
- Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT (2017) (33)
- Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. (2019) (33)
- Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT (2016) (33)
- Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study (2016) (33)
- Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT (2014) (32)
- Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study (2015) (32)
- Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. (2020) (32)
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
- Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT (2016) (32)
- Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission (2017) (32)
- An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. (2020) (32)
- Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. (2020) (32)
- Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide (2002) (32)
- Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies (2014) (32)
- Allogeneic hematopoietic stem cell transplantation for T‐prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM‐TC) (2015) (31)
- The polycomb group BMI 1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia (2007) (31)
- Blood dendritic cells in patients with acute lymphoblastic leukaemia (2004) (31)
- Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (2020) (31)
- The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (31)
- Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (31)
- Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center (2018) (31)
- Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party (2017) (31)
- Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. (2013) (30)
- CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges (2020) (30)
- Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? (2018) (30)
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma (2021) (30)
- Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. (2013) (30)
- Impact of HDAC inhibitors on dendritic cell functions. (2012) (30)
- Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC (2016) (30)
- Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin (2010) (30)
- Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia (2010) (30)
- Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. (2013) (30)
- Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors (2020) (30)
- Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? (2015) (30)
- Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. (2018) (30)
- Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation (2018) (29)
- Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study (2019) (29)
- Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. (2008) (29)
- Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT (2017) (29)
- Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution (2016) (29)
- Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey (2022) (29)
- Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT (2019) (29)
- Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis (2018) (28)
- T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis (2015) (28)
- Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia (2020) (28)
- Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT (2020) (28)
- Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (28)
- Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa (2016) (28)
- Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients. (2020) (28)
- High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? (2015) (28)
- RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT (2016) (28)
- ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. (2018) (27)
- Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen (2018) (27)
- Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. (2016) (27)
- Comprehensive Review of AL amyloidosis: some practical recommendations (2021) (27)
- Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation (2016) (27)
- Generation of potent T(h)1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells. (2002) (27)
- Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. (2019) (27)
- Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. (2017) (27)
- Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial (2014) (27)
- New Insight for the Diagnosis of Gastrointestinal Acute Graft-versus-Host Disease (2014) (27)
- Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT (2012) (27)
- Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years (2020) (26)
- Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. (2010) (26)
- Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study (2016) (26)
- 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study (2014) (26)
- Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. (2017) (26)
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) (26)
- Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT (2017) (26)
- Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial (2015) (26)
- Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation (2010) (26)
- Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT (2019) (26)
- Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (26)
- Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (26)
- Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial (2015) (26)
- Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort (2017) (25)
- Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis (2017) (25)
- Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. (2018) (25)
- Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2015) (25)
- Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T‐cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2018) (25)
- The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT (2013) (25)
- Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation (2015) (25)
- Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation (2021) (25)
- Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT (2017) (25)
- Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. (2014) (25)
- Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. (2015) (25)
- An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia (2017) (25)
- Imatinib: the narrow line between immune tolerance and activation. (2005) (25)
- Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (2018) (25)
- Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia (2018) (25)
- Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases (2009) (24)
- Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties (2016) (24)
- Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients (2011) (24)
- Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia (2020) (24)
- Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation (2018) (24)
- Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation (2016) (24)
- Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis (2018) (24)
- Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. (2013) (24)
- Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission (2006) (24)
- Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2020) (24)
- Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT (2016) (24)
- CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm (2020) (23)
- The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. (2014) (23)
- Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study (2018) (23)
- Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (23)
- Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) (2020) (23)
- Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. (2019) (23)
- Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2016) (23)
- Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation (2018) (22)
- Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation (2013) (22)
- Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. (2012) (22)
- Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia (2019) (22)
- Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee (2020) (22)
- Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (22)
- Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT (2019) (22)
- Plasmacytoid DCs and cancer: a new role for an enigmatic cell. (2004) (22)
- Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia (2020) (22)
- Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity (2012) (21)
- Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT (2019) (21)
- Increased plasmacytoid dendritic cells and RORγt‐expressing immune effectors in cutaneous acute graft‐versus‐host disease (2013) (21)
- Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (21)
- T‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2018) (21)
- Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia (2020) (21)
- Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant (2019) (21)
- The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party (2016) (21)
- Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level (2004) (21)
- Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT (2018) (21)
- Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party (2018) (21)
- Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. (2020) (21)
- Mobilized peripheral blood stem cells compared with bone marrow from HLA‐identical siblings for reduced‐intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT (2012) (21)
- Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT (2016) (21)
- Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. (2013) (21)
- Carboxypeptidase G2 Rescue in Delayed Methotrexate Elimination in Renal Failure (2000) (20)
- Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia (2020) (20)
- Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant (2010) (20)
- Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome (2012) (20)
- Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation (2012) (20)
- Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission (2017) (20)
- Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT (2012) (20)
- Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. (2018) (20)
- Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT (2017) (20)
- Venous thromboembolism in hematopoietic stem cell transplant recipients (2016) (20)
- Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients (2021) (20)
- Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting (2019) (19)
- Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease (2008) (19)
- Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. (2010) (19)
- A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties (2015) (19)
- Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. (2003) (19)
- Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation (2016) (19)
- A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on‐demand” scheme of administration at French autologous hematopoietic stem cell transplant programs (2015) (18)
- Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) (2017) (18)
- Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy (2015) (18)
- Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. (2011) (18)
- Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers (2017) (18)
- Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT (2017) (18)
- Anti‐thymocyte globulin improves survival free from relapse and graft‐versus‐host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia‐negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT (2018) (18)
- Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. (2002) (18)
- Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia (2021) (18)
- Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation (2018) (18)
- Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission (2017) (18)
- Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia (2018) (18)
- Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow T (2020) (18)
- Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. (2019) (17)
- Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. (2010) (17)
- Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study (2020) (17)
- Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT (2017) (17)
- Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (17)
- Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT (2021) (17)
- Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor (2012) (17)
- Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin (2019) (17)
- Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French–Italian 10-year experience on 228 patients (2020) (17)
- Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT (2015) (17)
- Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. (2013) (17)
- Individualized prediction of leukemia‐free survival after autologous stem cell transplantation in acute myeloid leukemia (2019) (17)
- Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome (2014) (17)
- Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
- Ruxolitinib For Patients With Primary Or Secondary Myelofibrosis before Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): A Retrospective Study Of The Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) (2013) (17)
- Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose? (2019) (17)
- Mechanisms of action of antithymocyte globulin: old dogs with new tricks! (2008) (17)
- Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party (2019) (17)
- Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease (2016) (16)
- Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study (2018) (16)
- Azacitidine after allo-SCT: the good without the bad? (2012) (16)
- Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT) (2013) (16)
- Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2014) (16)
- Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC (2014) (16)
- Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (2018) (16)
- Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study (2014) (16)
- Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. (2020) (16)
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis (2020) (16)
- Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. (2019) (16)
- Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC (2018) (16)
- Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA (2022) (16)
- Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update (2014) (16)
- Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. (2020) (15)
- Single‐agent thalidomide induces response in T‐cell lymphoma (2005) (15)
- Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT (2016) (15)
- Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. (2017) (15)
- European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization (2012) (15)
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (2018) (15)
- Mucosal‐associated Invariant Cells are Deficient in Systemic Sclerosis (2017) (15)
- CD34(+) immunoselected cells for poor graft function following allogeneic BMT. (2000) (15)
- Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial (2019) (15)
- Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation (2005) (15)
- Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. (2019) (15)
- Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. (2020) (15)
- Characterization of various blood and graft sources: a prospective series (2013) (15)
- Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. (2019) (15)
- Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. (2014) (15)
- Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma (2020) (15)
- Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study (2010) (15)
- Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. (2016) (15)
- CD34+-selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation. (2019) (15)
- Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report (2001) (15)
- Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati (2016) (15)
- Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over (2019) (15)
- Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission (2020) (14)
- Autologous Peripheral Blood Stem Cell Transplantation Following Heart Transplantation for Primary Systemic Amyloidosis (2001) (14)
- ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT (2017) (14)
- Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients? (2012) (14)
- Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? (2011) (14)
- Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. (2015) (14)
- Blood dendritic cells in patients with chronic lymphocytic leukaemia. (2008) (14)
- Infectious complications after post‐transplantation cyclophosphamide and anti‐thymocyte globulin‐based haploidentical stem cell transplantation (2019) (14)
- Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC (2018) (14)
- Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies (2021) (14)
- Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM (2018) (14)
- Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. (2021) (14)
- CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview (2020) (14)
- A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial (2015) (14)
- Understanding mortality in multiple myeloma: Findings of a European retrospective chart review (2019) (14)
- Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year‐old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT) (2015) (14)
- Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2016) (14)
- Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. (2014) (14)
- Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning (2013) (14)
- Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy (2021) (13)
- Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia (2018) (13)
- Prevention and treatment of relapse after stem cell transplantation by cellular therapies (2018) (13)
- Management of veno‐occlusive disease: the multidisciplinary approach to care (2017) (13)
- Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT) (2018) (13)
- Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series. (2012) (13)
- Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma (2012) (13)
- A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma (2022) (13)
- Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT (2011) (13)
- Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies (2019) (13)
- Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT (2019) (13)
- Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors (2010) (13)
- Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. (2010) (13)
- Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants. (2020) (13)
- Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (13)
- Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT (2017) (13)
- Allogeneic hematopoietic stem cell transplantation following reduced‐intensity conditioning regimen in children: a single‐center experience (2012) (13)
- Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (13)
- Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. (2019) (13)
- Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study (2018) (13)
- Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT (2016) (12)
- Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2018) (12)
- Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes (2019) (12)
- Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations (2015) (12)
- Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF (2012) (12)
- How we manage JAK inhibition in allogeneic transplantation for myelofibrosis (2015) (12)
- Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis. (2022) (12)
- Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT (2009) (12)
- Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (2016) (12)
- Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors (2009) (12)
- Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. (2011) (12)
- Dendritic cells and acute graft-versus-host disease after allogeneic stem cell transplantation (2007) (12)
- Impact of cyclosporine A concentration on acute graft‐vs‐host disease incidence after haploidentical hematopoietic cell transplantation (2019) (12)
- Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation (2019) (12)
- Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS (2016) (12)
- Safety and efficacy of rituximab in steroid-refractory chronic GVHD (2013) (12)
- Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma (2010) (12)
- Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission (2020) (11)
- Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission (2018) (11)
- Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT (2019) (11)
- Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia (2013) (11)
- Hematopoietic cell transplantation consideration for Philadelphia-like acute lymphoblastic leukemia patients. (2019) (11)
- Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia (2017) (11)
- Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia (2021) (11)
- What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease? (2018) (11)
- The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation (2019) (11)
- Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation (2007) (11)
- Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease. (2019) (11)
- Thiotepa‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (11)
- Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto‐SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM‐TC (2015) (11)
- Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia? (2014) (11)
- The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T‐cell therapy (2021) (11)
- AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation (2018) (11)
- Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study (2020) (11)
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT (2021) (11)
- Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. (2016) (11)
- FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. (2020) (10)
- Clonal haematopoiesis is increased in early onset in systemic sclerosis. (2020) (10)
- Impact of detectable measurable residual disease on umbilical cord blood transplantation (2020) (10)
- Younger donor’s age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2012) (10)
- Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party (2020) (10)
- Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT (2018) (10)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT). (2005) (10)
- Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT (2019) (10)
- Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. (2019) (10)
- Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults. (2017) (10)
- Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (2017) (10)
- Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. (2019) (10)
- Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. (2015) (10)
- Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status (2016) (10)
- Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (2013) (10)
- In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? (2015) (10)
- Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis (2016) (9)
- A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study (2021) (9)
- Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation. (2015) (9)
- Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. (2021) (9)
- Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. (2019) (9)
- Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) (2016) (9)
- Dendritic cells: interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3–8 March 2003 (2003) (9)
- Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT (2021) (9)
- Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation (2005) (9)
- Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients (2014) (9)
- Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT (2014) (9)
- Old dog, new trick: Trivalent arsenic as an immunomodulatory drug (2020) (9)
- Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France (2019) (9)
- Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT (2020) (9)
- Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy (2020) (9)
- Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3‐ and 6‐month time points (2015) (9)
- Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
- Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy (2015) (9)
- Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers (2013) (9)
- Graft‐versus‐host disease and graft‐versus‐leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT (2019) (9)
- Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease. (2015) (9)
- Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study (2021) (9)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A “Donor” vs. “No Donor” Comparison. (2006) (9)
- Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party (2020) (9)
- Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (2019) (9)
- Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation (2021) (8)
- Outcome of High-Risk and Refractory AML/MDS Patients Receiving a Flamsa Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT) (2011) (8)
- Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study (2019) (8)
- IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. (2021) (8)
- Current practices for screening, consent and care of related donors in France: Haematopoietic stem cell transplantation coordinator nurses’ perceptions (2017) (8)
- Regulatory B cell imbalance correlates with Tfh expansion in systemic sclerosis. (2020) (8)
- Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update (2022) (8)
- Impact of total body irradiation‐ vs chemotherapy‐based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia (2020) (8)
- Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2015) (8)
- T‐cell–depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT) (2018) (8)
- Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. (2016) (8)
- Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens (2008) (8)
- Generation of leukemic dendritic cells from patients with acute myeloid leukemia. (2003) (8)
- The EBMT: History, Present, and Future (2018) (8)
- Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-α inhibition (2020) (8)
- Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2015) (8)
- 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. (2015) (8)
- Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs (2018) (8)
- Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT (2022) (8)
- A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality (2014) (8)
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort (2019) (8)
- Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial (2016) (8)
- Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature. (2022) (8)
- Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. (2021) (8)
- Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma (2018) (8)
- Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2009) (8)
- Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center experience. (2020) (7)
- Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma (2012) (7)
- Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation. (2014) (7)
- Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 (2021) (7)
- OM-197-MP-AC adjuvant properties: the in vitro maturation of normal and leukemic dendritic cells in a serum-free culture model. (2004) (7)
- Handbook of Multiple Myeloma (2015) (7)
- Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation. (2017) (7)
- Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC (2020) (7)
- High‐dose post‐transplant cyclophosphamide impairs γδ T‐cell reconstitution after haploidentical haematopoietic stem cell transplantation using low‐dose antithymocyte globulin and peripheral blood stem cell graft (2020) (7)
- Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. (2014) (7)
- The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial (2018) (7)
- Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia (2021) (7)
- Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation (2018) (7)
- CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies (2022) (7)
- Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL (2003) (7)
- Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review (2016) (7)
- Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study. (2009) (7)
- Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. (2012) (7)
- Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT (2016) (7)
- Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial (2012) (7)
- Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT (2019) (7)
- Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft‐versus‐host disease (2015) (7)
- Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT (2014) (7)
- A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease (2021) (7)
- Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT (2013) (7)
- Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia (2004) (7)
- The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. (2020) (7)
- Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor (2019) (7)
- Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) (2008) (7)
- Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation? (2015) (7)
- Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT (2016) (6)
- Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria. (2007) (6)
- Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis. (2010) (6)
- Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT (2018) (6)
- Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant Disorders. A Eurocord-EBMT Analysis (2010) (6)
- How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation (2021) (6)
- Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (6)
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. (2022) (6)
- Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience (2020) (6)
- The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT) (2020) (6)
- Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk (2020) (6)
- The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood (2014) (6)
- Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? (2006) (6)
- Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation (2020) (6)
- Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT (2014) (6)
- Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial (2017) (6)
- Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process (2019) (6)
- Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2016) (6)
- Sustained response after reduced‐intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T‐cell non‐Hodgkin lymphoma (2008) (6)
- Reduced‐intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma (2006) (6)
- HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective series. (2013) (6)
- A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone (2017) (6)
- Requirements for operational cure in multiple myeloma. (2021) (6)
- Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the (2021) (6)
- Fertility preservation from the point of view of hematopoietic cell transplant specialists—a worldwide-web-based survey analysis (2019) (5)
- Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. (2019) (5)
- [New molecular targets and new clinical practices for hematopoietic stem cell mobilization]. (2011) (5)
- Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status (2020) (5)
- Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial (2016) (5)
- Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis (2021) (5)
- Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. (2020) (5)
- One Year into the COVID-19 Pandemic (2021) (5)
- Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases (2016) (5)
- Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia (2022) (5)
- Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity (2014) (5)
- First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes. (2013) (5)
- Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? (2017) (5)
- Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation (2021) (5)
- Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission (2020) (5)
- Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia (2019) (5)
- Outbreak of OXA-48-producing Enterobacterales in a haematological ward associated with an uncommon environmental reservoir, France, 2016 to 2019 (2021) (5)
- Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia (2020) (5)
- Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma (2020) (5)
- Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC (2018) (5)
- Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods (2021) (5)
- Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later (2009) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic? (2021) (5)
- Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party (2014) (5)
- Outcome of T‐cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (5)
- Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT (2017) (5)
- Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. (2021) (5)
- Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. (2020) (5)
- Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation (2015) (5)
- Exploring the microvascular impact of red blood cell transfusion in intensive care unit patients (2019) (5)
- Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program (2020) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC) (2016) (5)
- Plerixafor Is Highly Effective for the Mobilization of Autologous PBSC for Transplant in Children Failing to Mobilize by Conventional Means: International Experience with 40 Children From 19 Centers (2011) (5)
- Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved? (2012) (5)
- The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA‐matched allogeneic stem cell transplantation (2019) (5)
- Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT) (2022) (5)
- Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia (2016) (5)
- Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). (2022) (5)
- Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party (2020) (4)
- Venetoclax does not impair activated T-cell proliferation (2021) (4)
- Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2021) (4)
- A bit of antithymocyte globulin can take you a long way! (2012) (4)
- TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study (2019) (4)
- Treatment of Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome: A Large-Scale Study On Behalf of the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) (2012) (4)
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study (2021) (4)
- Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients? (2020) (4)
- Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults (2014) (4)
- CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort (2019) (4)
- Palifermin in Myelotoxic Therapy-Induced Oral Mucositis (2012) (4)
- Phase II Prospective Multicenter Study of Treosulfan Based Reduced intensity Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor (2010) (4)
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study (2022) (4)
- Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT (2021) (4)
- A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry (2021) (4)
- Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients. (2016) (4)
- Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT (2013) (4)
- 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. (2022) (4)
- Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT (2022) (4)
- Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (4)
- Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT (2021) (4)
- Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. (2022) (4)
- Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease (2022) (4)
- Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen (2012) (4)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison. (2007) (4)
- Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. (2022) (4)
- Inflammatory bowel disease after allogeneic stem cell transplantation (2015) (4)
- Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning (4)
- Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party (2018) (4)
- Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT (2010) (4)
- Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT (2022) (4)
- Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT (2014) (4)
- Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation. (2020) (4)
- Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (4)
- Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom (2020) (4)
- Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT (2015) (4)
- Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study (2012) (4)
- Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. (2022) (4)
- Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission (2019) (3)
- TFH cells in systemic sclerosis (2021) (3)
- Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia (2022) (3)
- The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML (2022) (3)
- Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. (2021) (3)
- Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study (2020) (3)
- Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT. (2022) (3)
- Paroxysmal Nocturnal Hemoglobinuria (PNH): Long-Term Epidemiological Study. (2006) (3)
- Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for > 55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT (2014) (3)
- Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. (2022) (3)
- Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients (2014) (3)
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study (2020) (3)
- The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation (2009) (3)
- The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2011) (3)
- 5-Azacytidine (AZA) Compared to Intensive Chemotherapy in Elderly Acute Myeloid Leukemia (AML) Patients: Results of a Retrospective Single Centre Matched Analysis, (2011) (3)
- The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (3)
- Transplant to treatment-free remission: the evolving view of ‘cure’ in chronic myeloid leukemia (2015) (3)
- Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT (2020) (3)
- Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission (2021) (3)
- Impact of FAB classification on predicting outcome in acute myeloid leukemia , not otherwise specified , patients undergoing allogeneic stem cell transplantation in CR 1 (3)
- Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis (2022) (3)
- Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program (2021) (3)
- Growth factor‐associated graft‐versus‐host disease and mortality 10 years after allogeneic bone marrow transplantation (2012) (3)
- Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: Total Body Irradiation (TBI) Plus Cyclophosphamide (or Melphalan) Is Not Superior to BEAM, A Single Institution Experience (2010) (3)
- Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure (2014) (3)
- Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT (2012) (3)
- Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: The Experience of the French SFGM-TC Group (2010) (3)
- In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations (2022) (3)
- Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2013) (3)
- Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT (2008) (3)
- Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry (2021) (3)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). (2009) (3)
- Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT (2019) (3)
- HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015) (3)
- Lenalidomide as Salvage Therapy after Allogeneic Stem′Cell Transplantation in Multiple Myeloma (2008) (3)
- Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT (2020) (3)
- Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT (2020) (3)
- Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells (2013) (3)
- Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: Myeloablative, non-myeloablative, and beyond (2015) (3)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT. (2010) (3)
- Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls (2020) (3)
- Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease (2021) (3)
- Allogeneic haematopoietic cell transplantation for myelofibrosis: a real‐life perspective (2021) (3)
- Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT (2021) (2)
- Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study (2019) (2)
- Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT (2020) (2)
- Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT. (2019) (2)
- Adult acute lymphocytic leukemia: biology and treatment (2011) (2)
- The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison. (2004) (2)
- CD25 expression on donor CD8+ T cells and graft-versus-host disease. (2005) (2)
- Long-Term Follow-up of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML): A Survey of 3567 Patients From the Acute Leukemia Working Party of the EBMT. (2012) (2)
- Let's reconstitute microbiota diversity. (2021) (2)
- Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study. (2008) (2)
- Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (2020) (2)
- In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones (2021) (2)
- Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT (2014) (2)
- Safety of a Weekly Administration of 10 mg/kg of Liposomal Amphotericin B for Antifungal Prophylaxis in Allogeneic Stem-Cell Transplant and Acute Leukemia Patients. (2005) (2)
- In 2022, which is preferred: haploidentical or cord transplant? (2022) (2)
- Autologous Hematopoietic Cell Transplantation in Multiple Myeloma (2014) (2)
- Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry. (2008) (2)
- A novel mouse model of acute graft-versus-host disease based on chemotherapy conditioning and G-CSF mobilized graft (2019) (2)
- Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults (2017) (2)
- ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. (2022) (2)
- Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy (2020) (2)
- Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015) (2)
- Haploidentical transplantation: finally, some light. (2021) (2)
- Lenalidomide after Allogeneic Stem Cell Transplantation in Multiple Myeloma. (2007) (2)
- Efficacy and safety of rituximab for autoimmune neutropenia: a French case series and literature review. (2020) (2)
- Similar Outcome Between Siblings, Unrelated Donors and Cord Blood After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in Complete Remission (2012) (2)
- Patient and disease characteristics influencing the outcome of mobilization with plerixafor: large compassionate-use analysis by ECOSM (European Consortium for Stem Cell Mobilization) (2011) (2)
- Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party (2019) (2)
- Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies (2019) (2)
- Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies (2022) (2)
- Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis. (2022) (2)
- Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems (2012) (2)
- Introduction: Why alternative donor transplantation and what are the different options and current challenges? (2016) (2)
- Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell. (2020) (2)
- Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! (2009) (2)
- Prediction of allogeneic HSCT related mortality in acute leukemia: exploring boundaries of prediction through machine learning based modeling. A data mining study from the acute leukemia working party (ALWP) of the EBMT (2014) (2)
- Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics (2019) (2)
- Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT (2021) (2)
- Effect of Graft Source on Alternative Unrelated Donor Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukaemia after: A Study from the SFGM-TC (2014) (2)
- Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT (2018) (2)
- Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT (2012) (2)
- Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT (2021) (2)
- Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient (2022) (2)
- RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT (2014) (2)
- Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better (2020) (2)
- Clinical Guide to Transplantation in Lymphoma: Savani/Clinical Guide to Transplantation in Lymphoma (2015) (2)
- HLA-haploidentical transplantation for relapsed/refractory AML: better LFS with BM than with PBSC in patients ≥ 55 years of age. (2022) (2)
- PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS (2019) (2)
- Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties (2014) (2)
- Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study (2021) (2)
- Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT (2018) (2)
- How I treat triple‐class refractory multiple myeloma (2022) (2)
- Updated Analysis of Hematopoietic Stem Cell Transplantations after Reduced Intensity Conditioning Regimen (RIC HSCT) for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry. (2005) (2)
- Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT (2018) (2)
- Comparison of RIC-alloHCT and autoHCT for > 55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT (2015) (2)
- New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia (2023) (2)
- Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT (2022) (2)
- French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry (2022) (2)
- Impact Of Rabbit Anti-Thymocyte Globulin-Containing Reduced-Intensity Conditioning Regimens On Outcomes Of Adults Undergoing Unrelated Cord Blood Transplantation For Hematological Malignancies (2013) (2)
- Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT (2022) (2)
- Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a Retrospective Study of 629 Patients From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). (2009) (2)
- Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT), (2011) (2)
- Features and Risk Factors of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib. (2006) (2)
- Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party (2016) (2)
- Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (2)
- Prospective Comparison Of Five Viral Infections (HHV6, CMV, EBV, ADV, BKv) After Umbilical Cord Blood (UCB) Vs PBSC Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (allo-SCT) In Adults (2013) (2)
- Maintenance after allogeneic HSCT in acute myeloid leukaemia. (2020) (2)
- FDG-PET/CT for the detection of gastrointestinal graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (2011) (2)
- Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT (2014) (2)
- A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT (2015) (1)
- Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO). (2009) (1)
- Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (AML) with 11q23 (MLL) Rearrangement (MLL-r AML). A Retrospective Analysis From the Acute Leukemia Working Party of EBMT (2011) (1)
- Impact of Azacitidine (AZA) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Myelodysplastic Syndromes (MDS): A Large-Scale Study on Behalf of the SFGM-TC and GFM Groups (2011) (1)
- Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT (2021) (1)
- Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT (2021) (1)
- No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients (2015) (1)
- Similar Outcome Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning in Children: A Retrospective Study from the SFGM-TC (2014) (1)
- Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study (2022) (1)
- Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation. (2021) (1)
- Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients. (2019) (1)
- Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (2016) (1)
- Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT (2022) (1)
- Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (1)
- The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study (2020) (1)
- Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. (2022) (1)
- Autologous Stem Cell Transplantation For Adult Burkitt Lymphoma In The Rituximab Era: A Retrospective Study Of The Lymphoma Working Party (LWP) Of The European Group For Blood and Marrow Transplantation (EBMT) (2013) (1)
- Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT (2011) (1)
- Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia Working Party Registry (2015) (1)
- Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. (2021) (1)
- 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. (2015) (1)
- The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation – a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR (2018) (1)
- Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT (2014) (1)
- Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Aurvey From the Acute Leukemia Working Party of EBMT (2011) (1)
- Clinical Hematology International: Why a New Journal in Hematology? (2019) (1)
- Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT (2015) (1)
- Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT (2013) (1)
- Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT) (2013) (1)
- Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT (2016) (1)
- Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do? (2020) (1)
- Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT (2014) (1)
- Association Between The Hematopoietic Cell Transplantation-Specific Comorbidity Index (CIn) And Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1) (2010) (1)
- Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma (2018) (1)
- COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease (2021) (1)
- Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation (2015) (1)
- Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study (2015) (1)
- Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin (2011) (1)
- A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome (2019) (1)
- Machine learning based predictive modeling for mortality 100 days post allogeneic hematopoietic stem cell transplantation (ALLO-HSCT) in acute leukemia: an EBMT-acute leukemia working party (ALWP) registry study (2014) (1)
- Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. (2019) (1)
- Safety of a Weekly Administration of 7.5 mg/kg of Liposomal Amphotericin B (LAB) for Antifungal Prophylaxis in Patients Receiving High Dose Corticosteroids (CS) for Acute GVHD after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (1)
- Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT (2021) (1)
- Reply to K. Filanovsky et al (2010) (1)
- Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) (2010) (1)
- Impact of Antithymocyte Globulins on Patient Outcome after Myeloablative Bone Marrow Stem Cell Transplantation from HLA 10/10-Matched Unrelated Donor: A Report from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) (2014) (1)
- Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study (2022) (1)
- Reply to J.J. Boelens et al. (2018) (1)
- PS1241 CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES (2019) (1)
- Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study (2017) (1)
- Impact of ABO-Mismatching Following HLA- Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for AML—a Report From the ALWP of the EBMT (2017) (1)
- HLA-A, -B, -C and –DRB1 High Resolution Matching Can Improve Patient' Outcome After Double Umbilical Allogeneic Stem Cell Transplantation (allo-SCT) (2013) (1)
- Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation (2010) (1)
- Inflammatory Cytokines and Acute Graft-Versus-Host Disease (aGVHD) after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (1)
- Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the Société Française de Greffe de Moelle et Thérapies Cellulaires (2015) (1)
- A haploidentical may be a better choice than a female genoidentical donor to transplant a patient with high risk acute myelogenous leukemia in first remission (2019) (1)
- Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-T (2016) (1)
- Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party (2013) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
- Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study (2018) (1)
- Human leukocyte antigen‐haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia‐free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age (2022) (1)
- Upfront Allogeneic-Stem Cell Transplantation for Patients with Non-Localized Untreated Peripheral T-Cell Lymphoma: An Intention-to-Treat Analysis from a Single Center (2014) (1)
- Impact of Minimal Residual Disease at Unrelated Cord Blood Transplantation In Children with Acute Lymphoblastic Leukemia In Remission: a Study on Behalf of Eurocord-EBMT and EBMT-PDWP (2010) (1)
- Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study (2016) (1)
- Long-Term Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation as Salvage Therapy for Young Patients after Relapse or Graft Failure: Experience at a Single Institution (2013) (1)
- Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT (2011) (1)
- Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation (2014) (1)
- Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia (2022) (1)
- Outcome of treatment for first versus later relapse in multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (1)
- Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2020) (1)
- Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma (2022) (1)
- Current update on reduced intensity regimens for allogeneic stem cell transplantation (2005) (1)
- Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases (2022) (1)
- Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. (2022) (1)
- LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy (2021) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (1)
- Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (1)
- Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation (2015) (1)
- Autologous Stem Cell Transplantation (auto-SCT) in Elderly Patients with Multiple Myeloma (MM): Age per se Does Not Affect Outcome. (2007) (1)
- T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT (2013) (1)
- A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study (2018) (1)
- Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation (2022) (1)
- Fludarabine and Busulfan-Based Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Transplantation (allo-SCT) with or without Anti-Thymocyte Globulin (ATG): Comparison between Two Prospective Studies in Patients with Myeloid Malignancies. (2004) (1)
- Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) (1)
- Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT (2023) (1)
- Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases (2022) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT (2013) (1)
- Editorial: Strengths and Challenges of Allo-SCT in the Modern Era (2022) (1)
- Impact of dose intensity on unrelated cord blood transplantation outcomes in adults patients with acute leukemia: A Report from Eurocord, the ALWP and the Cord Blood Committee of the CTIWP of the EBMT (2016) (1)
- Mismatched Unrelated Donor Allo-SCT for AML after Reduced Intensity or Ablative Conditioning Regimen—A Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
- Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients (2017) (1)
- The Impact of Center Experience on Results of Reduced Intensity – Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) (2010) (1)
- Non-T Depleted Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Secondary Versus De Novo AML: A Study from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2023) (1)
- The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT (2018) (1)
- The role of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML): A donor versus no donor comparison (2005) (1)
- Different Approaches Of Allogeneic Stem Cell Transplantation For Acute Leukemias In Suzhou (China) Lead To Similar Outcome Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis (2013) (1)
- Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party (2019) (1)
- Is There a Stronger Graft-Versus-Leukemia Effect Using HLA-Haplo-Identical Donors Compared to HLA-Identical Sibling Donors? (2015) (1)
- Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire. (2008) (1)
- Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT in BONE MARROW TRANSPLANTATION, vol 45, issue , pp S21-S22 (2010) (1)
- Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT (2020) (1)
- [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]. (2003) (1)
- Looking Ahead: Clinical Hematology International Turns One (2020) (1)
- Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party (2022) (1)
- Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT (2022) (1)
- Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. (2022) (1)
- Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis (2021) (1)
- Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT). (2007) (1)
- P039/O03 Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib (2019) (1)
- Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European society of Blood and Marrow Transplantation (EBMT) (2016) (1)
- Use of Busulfan in Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Adults: A Survey By the Complications and Quality of Life Working Party of the EBMT (2017) (1)
- Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation (2017) (1)
- Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma (2019) (1)
- Frontline induction therapy for multiple myeloma (MM) in real-world clinical practice: Third interim analysis of the multinational, observational EMMOS study (NCT01241396) (2015) (1)
- Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study (2020) (1)
- Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) (2021) (1)
- Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. (2014) (1)
- Daratumumab in transplant regimens for myeloma? (2020) (1)
- Rituximab in Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia With Fludarabine + Total Body Irradiation Conditioning: Results of a Phase II Prospective Multicenter Study (Itac 02-02) (2010) (1)
- Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT (2015) (1)
- The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations (2021) (1)
- Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study (2020) (1)
- Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
- Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study (2015) (1)
- Actinomycosis in a mandibular necro-osteolytic lesion in a patient with multiple myeloma treated with bisphosphonates. (2022) (1)
- Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France (2016) (1)
- Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation (2022) (1)
- Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT (2010) (1)
- Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients with Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in France. (2015) (1)
- O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC (2013) (1)
- All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study (2022) (1)
- To RIC or not to RIC: that is the question (2015) (1)
- Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit (2022) (1)
- Extending Autologous Hematopoietic Stem Cell Transplantation As First Line Treatment in Multiple Myeloma Patients with Severe Renal Impairment: A Retrospective Study of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) (2016) (1)
- FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT (2018) (1)
- Immunotherapy for Multiple Myeloma (2012) (1)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): A Donor Versus No Donor Comparison. (2005) (1)
- Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment (2022) (1)
- Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice (2015) (1)
- Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study (2019) (1)
- Extracorporeal Photopheresis for First Line Treatment of Acute Graft Versus Host Disease (2018) (1)
- Nutritional Supplements and Complementary/Alternative Medications in Patients With Hematologic Diseases and Hematopoietic Stem Cell Transplantation. (2021) (1)
- First Line Therapy with Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete Remission. (2004) (1)
- Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters (2022) (1)
- The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities (2022) (1)
- Outcome after Relapse or Progression Following First Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia. a Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (2014) (1)
- GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT (2023) (1)
- Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (1)
- Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis (2022) (0)
- 5-Azacytidine (5-AZA) Salvage Therapy for Very High Risk Acute Myeloid Leukemia (AML): Response After 3 Cycles Is the Major Determinant for Outcome. (2009) (0)
- Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT (2020) (0)
- Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients (2022) (0)
- Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT (2020) (0)
- P-212 Therapeutic management of MDS patients relapsing after allo-SCT: A large-scale study on behalf of the SFGM-TC (2013) (0)
- Unmanipulated Graft Haploindentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT) (2013) (0)
- Impact of alemtuzumab versus anti-thymocyte globulin after unrelated allogeneic stem cell transplantation with reduced-intensity conditioning as treatment for AML in CR1: a survey from the Acute Leukaemia Working Party of the EBMT (2012) (0)
- Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. (2023) (0)
- A Pooled Analysis of Survival By Defibrotide Timing of Initiation in Adults with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Following Hematopoietic Stem Cell Transplant (HSCT) (2018) (0)
- Impact of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT). (2008) (0)
- Impact of drug development on the use of stem cell transplantation. A report by the activity survey of the European Society for Blood and Marrow Transplantatio (EBMT) (2016) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) (2015) (0)
- Stem Cell Mobilization in Poor Mobilizers Using Plerixafor and G-CSF with or without Chemotherapy: A European Perspective (2011) (0)
- Platelets Recovery and Transfusion Needs after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (0)
- Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2023) (0)
- P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP (2022) (0)
- Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (0)
- [Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]. (2005) (0)
- Impact Of Cyclosporine A (CsA) Concentration On The Incidence Of Severe Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2009) (0)
- THIOTEPA-BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA (AML) - A SURVEY FROM THE ALWP OF THE EBMT (2014) (0)
- Contribution of IPSS-R Cytogenetics to Predict Outcome after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study from the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) (2014) (0)
- Impact of plasmacytoid dendritic cell recovery on outcome after reduced-intensity conditioning allogeneic stem cell transplantation (2005) (0)
- Regulation of Dendritic Cell Function with Immunomodulatory Drugs (2005) (0)
- Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT (2022) (0)
- Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation (2022) (0)
- Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT (2019) (0)
- TRANSPLANTATION Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation Group of Bone Transplantation (2015) (0)
- Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study (2015) (0)
- Defining the Prognostic Implications of Recurring Cytogenetic Aberrations and FLT3-ITD in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation: On Behalf of the ALWP of the EBMT (2019) (0)
- Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR (2015) (0)
- P-182: Comparison of lenalidomide, bortezomib, dexamethasone vs bortezomib, cyclophosphamide, dexamethasone as an induction regimen in newly diagnosed myeloma patients eligible for intensive chemotherapy (2021) (0)
- CT-028 Clofarabine and Total Body Irradiation as a Conditioning Regimen for Allogeneic Stem Cell Transplantation in High-Risk Acute Leukemia. (2022) (0)
- Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: Lessons from Experience (2008) (0)
- Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia (2014) (0)
- Unrelated cord blood (ECB) transplantation for AML: higher incidence of acute GVHD and lower survival in male patients transplanted with female unrelated cord blood. A report from Eurocord and the ALWP of the EBMT (2015) (0)
- Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse (2017) (0)
- Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2014) (0)
- Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (0)
- Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma (2021) (0)
- Long-Lasting HHV-6 Reactivation and Immune Recovery In Adult Long-Survivors After Umbilical Cord Blood (UCB) Allo-SCT: A Comparison With PBSC As Stem-Cell Source (2013) (0)
- Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (Flu-Bu-ATG) Conditioning for Hematological Malignancies: A Multicenter ITAC Study (2009) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. (2012) (0)
- Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- Haploidentical Transplantation Outcomes for Secondary Acute Myeloid Leukemia—on Behalf of the ALWP of the EBMT (2018) (0)
- Hematopoietic Recovery and Transfusion Needs after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Adult Patients with Hematologic Malignancies (2018) (0)
- AB0161 CLONAL HEMATOPOIESIS IS INCREASED AND NOT RELATED TO AGING IN SYSTEMIC SCLEROSIS (2020) (0)
- Escalated lymphodepletion Followed by Donor Lymphocyte Infusion (DLI) can Induce a Graft-Versus-Host Response without Overwhelming Toxicity. (2009) (0)
- Comparison of outcomes after unrelated cord blood transplantation and matched unrelated donor reduced-intensity conditioning regimen transplantation for lymphoid malignancies - a Eurocord-Netcord Group/LWP and CLWP of the EBMT Study (2010) (0)
- S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS (2022) (0)
- Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT (2022) (0)
- Frontline treatment of multiple myeloma in the elderly (2013) (0)
- IV Busulfan-Based Reduced Intensity Regimen (RIC) Before Allogeneic Stem Cell Transplantation Is Well Tolerate And Effective In Patients With Hematological Diseases (2010) (0)
- Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (0)
- Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC) Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors (MUD). (2008) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center (2017) (0)
- Management of multiple myeloma first relapse after autologous hematopoietic stem cell transplantation (2016) (0)
- Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry (2022) (0)
- Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT (2022) (0)
- Posttransplant cyclophosphamide‐based anti–graft‐vs‐host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen‐mismatched unrelated donors versus haploidentical donors: A study o (2022) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe française De Greffe De Moelle Et De Therapie Cellulaire (2012) (0)
- Phenotypic and Functional Characterization Of a Novel Immature Hematopoietic Myeloid Suppressive Progenitor Cells Mobilized By G-CSF. Application To Gvhd Treatment (2013) (0)
- CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC (2015) (0)
- Outcomes of Defibrotide-Treated Patients (Pts) with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study (2022) (0)
- Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT (2013) (0)
- Outcomes After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) In 163 Pediatric Patients (<18 years old): A Retrospective Study On Behalf Of The SFGM-TC (2013) (0)
- Antithymocyte Globulins (ATG) As Part Of The Myeloablative Conditioning (MAC) Regimen Can Reduce The Risk Of Severe Graft-Vs.-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) From Matched-Unrelated Donors (MUD) [A SFGM-TC Study] (2009) (0)
- Allogeneic Stem Cell Transplantation from Two Loci Mismatched (≤6/8) Unrelated Donors in Acute Leukemia: On Behalf of the ALWP of the EBMT (2020) (0)
- Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03 (2022) (0)
- Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT (2021) (0)
- Allogeneic Stem Cell Transplantation from Haploidentical Versus Matched Sibling Donors for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2022) (0)
- CD8 T cell dose impacts acute graft-versus-host disease after reduced intensity conditioning (RIC) for allogeneic stem cell transplantation. (2004) (0)
- Early Detection of Acute Graft-Versus-Host Disease by Wireless Capsule Endoscopy Combined With Probe-Based Confocal Laser Endomicroscopy:Time to Change the Diagnostic Algorithm? (2011) (0)
- Non T–Cell Depleted Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (0)
- Allogeneic immunotherapy by hematopoietic stem cell transplantation (ASCT) after reduced intensity conditioning (RIC) following high-dose chemotherapy for patients with acute myeloblastic leukemia (AML) in first complete remission (CR1): Reduced toxicity (2016) (0)
- Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT (2015) (0)
- Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults (2014) (0)
- Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT. (2012) (0)
- Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases (2015) (0)
- Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers (2015) (0)
- Risk Factors for Graft-versus-Host Disease (GVHD) Following Myeloablative HLA-Identical Sibling Transplantation with Allogeneic Peripheral Blood Stem Cells (PBSC): An Analysis of 546 Patients. (2004) (0)
- Impact of plasmacytoid dendritic cells (PDC) on outcome after allogeneic stem cell transplantation (allo-SCT) (2013) (0)
- Myeloma immunotherapy: ready for prime time (2021) (0)
- Bone Marrow or Peripheral Blood Stem Cell Transplantation From Unrelated Donors in Adult Patients With Acute Myeloid Leukemia (2011) (0)
- Multi-Center Quantification Study of Time, Effort and Resource Utilization Associated with Autologous Peripheral Blood Stem Cell Mobilization: A European Perspective (2015) (0)
- Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC (2018) (0)
- Microparticles Derived from Myeloma Plasma Cells Released in the Microenvironment Boost Thrombin Generation. A Medialization Study (2019) (0)
- Abstracts of the Data Management GroupEBMT 2010 (2010) (0)
- From Ex-Vivo T-Cell Depletion to Post-Transplant Cyclophosphamide: Improved GvHD-Free & Relapse-Free Survival but Comparable Chronic GvHD Incidence in Haploidentical Transplantation. A 15 Years EBMT Registry Analysis on Behalf of the TCWP-EBMT (2019) (0)
- Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. (2022) (0)
- The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. (2019) (0)
- Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. (2023) (0)
- The cytokine storm and acute graft-versus-host disease (aGVHD) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) (2006) (0)
- Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT (2021) (0)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Refractory or Relapsed Non-Hodgkin’s Lymphoma (NHL). (2006) (0)
- Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up (2022) (0)
- Long term infectious complications following reduced intensity conditioning (RIC) allogeneic HLA-identical sibling transplantation (allo-SCT) (2005) (0)
- Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) (2012) (0)
- Association Of Health Care Expenditure With Results Of Allogeneic HSCT For Adults With ALL: An Analysis From Acute Leukemia Working Party Of The EBMT (2013) (0)
- Acute myeloid leukemia with FLT 3 mutation : a therapeutic window for targeted therapy after allogeneic hematopoietic cell transplantation ( alloHCT ) (2017) (0)
- CD34+ Selected Cells Boost for Poor Graft Function Post Allogeneic Stem Cell Transplantation (2016) (0)
- Systemic lupus erythematosus. (2008) (0)
- Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome (2015) (0)
- Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) For Patients Aged ≥60 Years: A Retrospective Analysis Of 629 Patients From The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) (2010) (0)
- Graft-Versus Host Disease (GVHD) and Infectious Complications Following Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults. (2007) (0)
- Outcome of Relapse After Allogeneic Transplantation for Childhood Acute Lymphoblastic Leukemia In Complete Remission. A Study of the Pediatric Diseases and Acute Leukemia Working Parties of the EBMT Group (2010) (0)
- Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT (2013) (0)
- Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study (2022) (0)
- Brentuximab Vedotin for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a report from the EBMT Lymphoma Working Party (2020) (0)
- Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE) (2023) (0)
- Plasmacytoid Dendritic Cells (PDC) and Th17 Immune Response Contribution in Skin Acute Graft-Versus-Host-Disease (GVHD) (2011) (0)
- Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin (2010) (0)
- Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT. (2010) (0)
- Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party (2022) (0)
- Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) (2010) (0)
- Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT (2019) (0)
- Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). (2023) (0)
- Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord (2018) (0)
- Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study. (2018) (0)
- Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in France (2017) (0)
- Autologous and Allogeneic Stem Cell Transplantation for Richter's Transformation: A Retrospective Analysis From the Chronic Leukaemia Working Party and Lymphoma Working Party of the EBMT. (2009) (0)
- Allogeneic Stem Cell Transplantation from Matched Related Donor in Patients Over the Age of 55 Years After Reduced Intensity Conditioning Associating Fludarabine-Iv Busulfan and Rabbit-Antithymocyte Globulin: A Prospective Multicenter Phase II Clinical Trial with Socio Economic Evaluation (2012) (0)
- A Delayed Innate T Cell Reconstitution Is Associated with Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation Using Anti-Thymoglobulin and High-Dose Post-Transplant Cyclophosphamide (2018) (0)
- S117 THE ROLE OF ANTI-THYMOCYTE GLOBULIN WITH THIOTEPA-BUSULFAN-FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST-TRANSPLANT CYCLOPHOSPHAMIDE (2019) (0)
- Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature (2020) (0)
- Autologous Versus Haploidentical Stem Cell Transplantation in Adult Patients with Intermediate Risk Actue Myelogenous Leukemia in First Complete Remission and Undetectable Minimal Residual Disease: A Global Preliminary Analysis of Chinese Data (2022) (0)
- Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries (2023) (0)
- Outcome After 9/10 Mismatched Unrelated Donor or Cord Blood Cells Allogeneic Stem Cell Transplantation (allo-SCT) in the Setting of Reduced-Intensity Conditioning (RIC) (2012) (0)
- Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study (2021) (0)
- Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation (0)
- Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML) (2013) (0)
- Animal immunized Horse Rabbit Rabbit Human cells for the immunization of the animal Thymocytes Thymocytes Jurkat cells (2015) (0)
- Acute myeloid leukemia Prognostic signi fi cance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia (2019) (0)
- Outcomes of Unrelated Cord Blood Transplantation in Patients with Multiple Myeloma a Eurocord, CBC-Cellular Therapy & Immunobiology Working Party and Chronic Malignancies Working Party-EBMT Study (2015) (0)
- Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT) (2015) (0)
- News from ASH 2016 about the multiple myeloma (2017) (0)
- Real-World Clinical Outcomes By Cytogenetic Risk Category in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France (2016) (0)
- S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD (2019) (0)
- Current Developments and Perspectives in Multiple Myeloma (2014) (0)
- New strategies of allogeneic hematopoietic stem cell transplantation with the use of haploidentical donors (2016) (0)
- Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation Transplantation and Cellular Therapy (2022) (0)
- Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD). (2016) (0)
- S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT (2019) (0)
- Predictive factors and impact of full donor T-cell chimerism after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) (2006) (0)
- Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial (2022) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin (ATG) Compared to Fludarabine and Low Dose Total Body Irradiation (TBI) for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Patients with Lymphoid Malignancies. (2010) (0)
- Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation (2018) (0)
- Impact of Pre-Emptive Rituximab Treatment for Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Longitudinal Study of 110 Patients (2017) (0)
- Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT (2020) (0)
- Chronic Graft versus Host Disease: Interdisciplinary Management: Spectrum of Chronic Graft versus Host Disease in Unique Clinical Situations: The Role of Stem-Cell Source Including Cord Blood Stem Cells, Reduced-Intensity Conditioning, and Donor Leukocyte Infusions (2009) (0)
- Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis. (2023) (0)
- European paediatric experience with plerixafor for autologousPBSC mobilization from children failing to mobilize PBSC byconventional means: an initial series of 6 patients from 2centres. (2011) (0)
- Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT (2012) (0)
- Autologous Stem Cell Transplantation For Acute Leukemias In Suzhou (China): Similar Outcome In CR1 Patients Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis (2013) (0)
- Donor Lymphocyte Infusion Vs. Second Allogeneic HCT In Relapsed AML After Allografting: A Landmark Analysis From The Acute Leukemia Working Party Of EBMT (2013) (0)
- Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia (2017) (0)
- Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF:impact of apheresis volume. Data from the Plerixafor European Compassionate Use Study. (2011) (0)
- Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study (2019) (0)
- Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1) (2021) (0)
- Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT. (2012) (0)
- P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (2022) (0)
- 133 UNRELATED CORD BLOOD OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS RECEIVING A REDUCED INTENSITY CONDITIONING REGIMEN: AN EBMT STUDY (2015) (0)
- Impact of Conditioning Regimen on Outcomes of T-Replete Haplo-Identical Transplantation for Patients Over 45 Years-Old with AML: A Study On Behalf Of the Acute Leukemia Working Party of the EBMT (2017) (0)
- High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM). (2007) (0)
- Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC (2015) (0)
- Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis (2013) (0)
- The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) (2007) (0)
- Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO). (2009) (0)
- Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study (2022) (0)
- Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients (2021) (0)
- Exploring limiting factors in the prediction of allogeneic HSCT related mortality: an in-silico machine learning analysis of the acute leukemia working party (ALWP) registry of the EBMT (2015) (0)
- Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Investigating Antibiotic Exposure and Risk of Severe Acute Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (2019) (0)
- WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. (2022) (0)
- Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT (2016) (0)
- CD8 T cell dose impacts acute graft-versus-host disease after reduced intensity conditioning (RIC) for allogeneic stem cell transplantation (2004) (0)
- Checkpoint Inhibition Before Haploidentical Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma (Hl) Patients is Associated with Higher PFS without Increased Toxicities (2019) (0)
- Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT (2013) (0)
- Comparable survival for poor-risk cytogenetics AML in first complete remission after haploidentical donor or unrelated donor transplantation: a study from the ALWP of EBMT (2016) (0)
- Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis (2022) (0)
- Role of the graft-versus-leukaemia effect after reduced-intensity conditioning allogeneic stem cell transplantation as treatment for acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of the EBMT (2010) (0)
- Prognostic Indexes Is Not Predictive Of Treatment Related Mortality In Patients (pts) Older Than 60 Years Treated With Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation (RIC-ALLO) (2010) (0)
- TFH cells in systemic sclerosis (2021) (0)
- Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplasic Syndrome Who Received Conditioning Regimen Based on Fludarabin, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
- Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Secondary Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS). (2005) (0)
- Winning Cord Blood Unit Characteristics Impacting on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: a Collaborative Study of Eurocord and the Acute Leukemia Working Party of EBMT (2016) (0)
- Plasma Proteomic Profiles May Predict Early Acute Graft-vs.-Host Disease (aGVHD) Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT). (2006) (0)
- KIR-Ligand Incompatibility in the Graft-Versus-Host Direction Is Associated with Better Outcomes after Unrelated Cord Blood Stem Cell Transplantation for Acute Leukemia in Complete Remission (2008) (0)
- The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities (2022) (0)
- Lymphodepleting Conditioning Regimens (2022) (0)
- P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE (2022) (0)
- HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST‐TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP (2019) (0)
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT (2014) (0)
- A composite discipline that moves forward (2017) (0)
- Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Pooled Analysis of Defifrance and EBMT PASS Registries (2022) (0)
- Prior Treatment with Chemotherapy Associated to Gemtuzumab Ozogamicin (GO) Does Not Increase the Risk of Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell Transplantation (all-SCT). (2008) (0)
- Reduced-Intensity (FB2) Vs Reduced-Toxicity Myeloablative (FB3/FB4) Fludarabine/Busulfan Based Conditioning Regimens for Non-Hodgkin Lymphoma (NHL) Allografted Adult Patients: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2016) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen for Elderly Patients (60 years and older) with Hematological Malignancies Using Unrelated Donors: A Retrospective Study on Behalf of the French Society for Stem Cell Transplantation and Cell Therapies (2014) (0)
- Low incidence of hyperacute graft‐versus‐host disease (GVHD) with effective GVHD prophylaxis based on anti‐thymocyte globulin (2022) (0)
- The Use of Recombinant Human Erythropoietin (rHuEpo) after Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation (ASCT) Reduce Red Blood Cell (RBC) Transfusion Requirements. (2006) (0)
- The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment : A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (0)
- Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia (2016) (0)
- Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide (2011) (0)
- Rituximab (RTX) as Salvage Therapy for Refractory Chronic Graft-Versus-Host Disease (cGVHD). (2007) (0)
- Defibrotide – A New Treatment Approach for Severe Veno-occlusive Disease (2015) (0)
- Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Trans (2022) (0)
- Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy. (2012) (0)
- Increased Th17/Treg Ratio In Liver Chronic Graft-Versus-Host-Disease (2013) (0)
- Second Autologous Stem Cell Transplantation in Poor Stem Cell Mobilizers Multiple Myeloma Patients (2017) (0)
- Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT (2020) (0)
- Comparison of PBSC Vs Cord Blood (CB) As Stem Cells Source for Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Haematological Diseases: A Single Centre Analysis. (2012) (0)
- HLA disparities on unshared haplotype influence outcomes of unmanipulated haploidentical hematopoietic stem cell transplantation (HaploSCT): A Study from the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation (EBMT) (2016) (0)
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Following Total Body Irradiation- the Effect of Anti- Thymocyte Globulin on Transplant Outcome: ALWP of the EBMT Study (2019) (0)
- Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party (2022) (0)
- Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT (2020) (0)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Secondary Acute Myeloid Leukemia (AML) Following Breast Carcinoma. (2009) (0)
- Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC). (2009) (0)
- Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT (2019) (0)
- Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality (2008) (0)
- Cost-Effectiveness of Double-Unit Cord Blood Transplantation Versus Single-Unit Cord Blood Transplantation in Adult Patients with Acute Leukaemia in France- On Behalf of SFGM-TC, Eurocord, ALWP-EBMT (2011) (0)
- Outcomes of Acute Myelogenous Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Total Body Irradiation Versus Chemotherapy-Based Myeloablative Conditioning (2020) (0)
- Mise au point sur les indications du G-CSF pégylé (2009) (0)
- Peripheral Blood Stem Cell Grafts Mobilized by G-CSF and Plerixafor in Comparison to G-CSF Alone: Phenotypic and Functional Characterization, (2011) (0)
- Plasmacytoid Dendritic Cells (PDC) and Th17 Immune Response Contribution in Gut Acute Graft-Versus-Host-Disease (GVHD) (2011) (0)
- Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party (2012) (0)
- Impact of antithymocyte globulin (ATG)-containing conditioning regimens on patients undergoing allogeneic stem cell transplantation (allo-CST) for poor risk cytogenetic IPSS myelodysplastic syndrome (PRC-MDS): A report from the French Society of Stem Cell Transplantation and Cell Therapy (SFGM-TC). (2017) (0)
- KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries (2021) (0)
- PS1416 EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK (2019) (0)
- 356: First line sequential therapy with intensive consolidation chemotherapy and allogeneic hematopoietic stem cell transplantation (ASCT) after reduced intensity conditioning (RIC) for patients with acute myeloblastic leukemia (AML) in first complete remission (CR1) (2007) (0)
- Nuke less for less cancer. (2019) (0)
- Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT (2016) (0)
- Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study (2019) (0)
- CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2022) (0)
- Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia (2014) (0)
- Prospective Comparison of Reduced Intensity (Flu-Bu-ATG) vs. Non-Myeloablative (Flu-TBI) Conditioning For Matched Related allo-SCT: A Clinical and Cost-Effectiveness Multicenter ITAC Study (Mini vs. Micro Trial) (2010) (0)
- Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning for adults with Ph(-) all undergoing Allo-Hct. A study from the Acute Leukemia Working Party of the EBMT. (2017) (0)
- Isatuximab plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. (2022) (0)
- Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry (2022) (0)
- Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis (2022) (0)
- Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla (2023) (0)
- Defibrotide (DF) Treatment in Pediatric (ped) and Adult Patients (pts) with Severe or Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Final Results from the Defifrance Study (2022) (0)
- Interleukin-22 modulating properties in graft-versus-host disease (2016) (0)
- Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC)Allogeneic HLA-Identical Sibling Transplantation (allo-SCT). (2006) (0)
- DEFIBROTIDE TREATMENT IN PAEDIATRIC PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE INTERIM RESULTS (2020) (0)
- Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study (2022) (0)
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS FEASIBLE AFTER SOLID ORGAN TRANSPLANTATION: FINAL ANALYSIS BY THE EARLY COMPLICATIONS SUBCOMMITTEE OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY, EBMT (2014) (0)
- The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation (2011) (0)
- 198: The use of recombinant human erythropoietin (rHuEpo) after reduced intensity conditioning (RIC) allogeneic hematopoietic peripheral blood stem cell transplantation (ASCT) reduces red blood cell (RBC) transfusion requirements (2007) (0)
- Haploidentical stem cell transplantation abrogates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT (0)
- MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2021) (0)
- Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation (2015) (0)
- Respiratory Infection with Non-Tuberculous Mycobacteria After Allogeneic Hematopoietic Stem Cell Transplantation (2019) (0)
- General Indications and Logic for Haploidentical SCT (2017) (0)
- Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma (2016) (0)
- General Management of the Patient Topic leaders: Carlo Dufour, Silvia Montoto and John Murray (2019) (0)
- Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis (2023) (0)
- Posaconazole as Prophylaxis in Immunocompromised Patients: A Single Center Experience (2008) (0)
- Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2022) (0)
- The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC). (2007) (0)
- P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 (2022) (0)
- Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) (0)
- Impact of Cytopenias in Patients Treated with Ruxolitinib Versus Best Available Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease: A REACH2 Post Hoc Analysis (2023) (0)
- Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2021) (0)
- Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party (2022) (0)
- Bone marrow transplantation. Preface. (2014) (0)
- HSCT Complications and Management Topic leaders: Jan Styczynski, Enric Carreras and Per Ljungman (2019) (0)
- Treatment of transplant-eligible patients (2015) (0)
- Related-donors care: coordinatoor nurses’ point of view (2017) (0)
- Arsenic Trioxide Induces Apoptosis and Regulatory Functions of Plasmacytoid Dendritic Cells (2018) (0)
- Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2022) (0)
- REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS (2017) (0)
- Common non-seasonal viral infections after hematopoietic stem cell transplantation (2013) (0)
- Proteasom inhibitors in multiple myeloma: an update (2015) (0)
- Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester (2019) (0)
- Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France (2023) (0)
- Immunomodulation by Lymphodepletion and Donor Lymphocyte Infusion to Treat Post Allogeneic Transplantation Relapse (2010) (0)
- Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group (2011) (0)
- Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial (2022) (0)
- Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (2015) (0)
- Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia (2020) (0)
- Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI (2022) (0)
- Impact of treatment prior to allogeneic stem cell transplantation for myelodysplastic syndromes: A study on behalf of the SFGM-TC and the GFM groups. (2017) (0)
- Plerixafor for stem cell mobilization in Hodgkin, non-Hodgkin,and multiple myeloma patients: a subgroup analysis from theEuropean Compassionate Use Program. (2011) (0)
- Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study (2022) (0)
- Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study (2020) (0)
- Reply to van de Loosdrecht et al (2003) (0)
- Bortezomib As Salvage Treatment for Multiple Myeloma Relapsing after Allogeneic Haematopoietic Stem Cell Transplantation: Efficacy, Tolerance and Modulation of Graft Versus Host Disease: A Study of the French Society for Stem Cell Transplantation and Cell Therapies (SFGM-TC) (2014) (0)
- Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: The Way Forward (2009) (0)
- Influence of Stem Cell Source (Bone Marrow versus Peripheral Blood) on Outcome after Reduced-Intensity Conditioning Regimens for Acute Leukemia—a Report from the Acute Leukemia Working Party of the EBMT (2015) (0)
- Stem cell mobilization in lymphoma patients (2015) (0)
- BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY (2017) (0)
- Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study (2014) (0)
- Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT) (2010) (0)
- Outcomes After a Sequential Clofarabine/Arac-C Chemotherapy Followed By Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) In Pediatrics Patients With JMML Or Primary/Relapsed Refractory AML: A Pilot Study (2013) (0)
- Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT (2022) (0)
- Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT (2018) (0)
- Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia - response to Houtenbos et al (2006) (0)
- Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant (2020) (0)
- Multi-Center Prospective Trial on Conditioning with Treosulfan, Fludarabine and ATG Before Allogeneic HSCT from Unrelated Donors. (2007) (0)
- Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Unrelated Cord Blood in Patients with T-Cell Non-Hodgkin Lymphoma : A Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGMC-TC) (2019) (0)
- Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study (2022) (0)
- CR1 acute myeloid leukemia and HLA-identical allogeneic transplantation (ASCT) prepared with reduced intensity regimen (RIC): leukemia control requires adequate pre graft chemotherapy and post graft GVHD (2004) (0)
- Reduced intensity conditioning regimen (RIC) followed by allogeneic stem cell transplantation (ASCT): Low related transplant mortality and high survival probability in patients with advanced solid tumors in a multicenter trial. (2004) (0)
- Tandem Auto-Allo in Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR). (2009) (0)
- Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia (2022) (0)
- A bit of sweetness for GVHD prevention. (2015) (0)
- Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party (2018) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT (2020) (0)
- An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party (2016) (0)
- An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. (2022) (0)
- Allogeneic Stem Cell Transplantation for AML Patients with RUNX1 Mutation in First Complete Remission: A Study on Behalf of the ALWP of the EBMT (2020) (0)
- Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation (2022) (0)
- CT-027: Multidimensional Geriatric Assessment for Elderly Hematological Patients (≥60 years) Submitted to Allogeneic Stem Cell Transplantation; A French-Italian 10-year Experience on 228 Patients (2020) (0)
- Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogenic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study (2011) (0)
- Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03) (2023) (0)
- Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. (2023) (0)
- Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP) (2021) (0)
- Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2023) (0)
- The role of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML): a donor versus no donor comparison (2005) (0)
- Factors determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a survey from the Acute Leukaemia Working Party of the EBMT (2015) (0)
- The Association Of Fludarabin, Oral Busulfan And Thymoglobulin Prior To Matched Related Allo-SCT Allows For High Long Term Outcome For Both Patients With Myeloid Or Lymphoid Malignancies: Long Term Analysis Of A Homogenous Cohort Of 100 Consecutive Patients (2010) (0)
- Refined graft-versus-host disease-free/relapse-free survival - a novel outcome endpoint for haploidentical transplantation in adults with acute leukemia: on behalf of ALWP-EBMT (2016) (0)
- Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of overwieght and obesity. (2011) (0)
- A Phase II Study of Yttrium-90-Ibritumomab Tiuxetan In Combination with a Fludarabine-Based Reduced Intensity Regimen Followed by Allogenic Stem Cell Transplantation In Patients with Relapsed or Chemorefractory CD 20 Positive Non-Hodgkin's Lymphoma. (2010) (0)
- Do ABC proteins still have a role to play in acute myeloid leukemia (2014) (0)
- Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience (2020) (0)
- Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated AML patients: on behalf of the ALWP/EBMT (2022) (0)
- Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2007) (0)
- FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring (2018) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (0)
- Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. (2023) (0)
- Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France (2022) (0)
- Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry (2016) (0)
- Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT (2012) (0)
- Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other (2020) (0)
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2021) (0)
- Evaluation of Infectious Complications after Haploidentical Stem Cell Transplantation in Adult Patients with Hematologic Malignancies (2017) (0)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia (CMML): Prognostic Factors for Survival. A Report From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC), (2011) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT). (2009) (0)
- prognosis of chronic myeloid leukemia The polycomb group BMI-1 gene is a molecular marker for predicting (2013) (0)
- Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT (2023) (0)
- Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2015) (0)
- Comparison of haplo-identical versus unrelated allogeneic stem cell transplantation for acute myeloid leukemia with active disease: A report of 1578 patients from Acute Leukemia Working Party of EBMT (2016) (0)
- Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) (2012) (0)
- Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS (2022) (0)
- Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population (2021) (0)
- Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT 3-ITD ; a study from the Acute Leukemia Working (2017) (0)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT, (2011) (0)
- Haematopoietic stem cell mobilization with plerixafor inpatients with non-haematological diseases (2011) (0)
- The hierarchy of alternative donors for allogeneic hematopoietic stem cell transplantation in poor risk Aml in CR1 revisited (2016) (0)
- A Scoring System Predicting Outcome After Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia (2011) (0)
- Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Pediatric Patients Ineligible for Standard Myeloablative Conditioning. (2010) (0)
- Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). (2014) (0)
- Impact of CD34+ Cell Dose on Clinical Outcomes after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from Haploidentical Donors in AML Patients. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT (2014) (0)
- A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) (2019) (0)
- [Can one separate GVH and GVT after allogenic hematopoietic stem cell transplantation?]. (2003) (0)
- Good Safety and Tolerance Profiles of Long Term Treatment of Advanced Multiple Myeloma (MM) with Bortezomib. (2007) (0)
- transplantation: long-term results of a randomized study Chronic graft-versus-host disease after allogeneic blood stem cell (2013) (0)
- The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe (2021) (0)
- Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. (2023) (0)
- Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients – A Report From The Acute Leukemia Working Party Of EBMT (2013) (0)
- Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia (2022) (0)
- Comorbidities in recipients of low transplant conditioning intensity regimens for acute myeloid leukemia: an ALWP EBMT study. (2023) (0)
- Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies (2021) (0)
- Current status of autologous stem cell transplantation for multiple myeloma (2019) (0)
- Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT. (2009) (0)
- Impact of Plasmacytoid Dendritic Cell (PDC) Recovery on Outcome after Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT). (2004) (0)
- Low-Dose Methotrexate as Salvage Therapy for Refractory Graft-Versus-Host Disease (GVHD) after Reduced-Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (0)
- CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission (2022) (0)
- Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation (2022) (0)
- Lymphoid Chimerism (LC) Kinetic after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (0)
- Zygomycosis After Allogeneic Hematopoietic Stem Cell Transplantation: A French Multicenter Cohort Study (2003-2008) (2010) (0)
- Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience (2015) (0)
- Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study (2022) (0)
- Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) (2013) (0)
- Allogeneic Stem Cell Transplantation (Allo-SCT) for De Novo Ph+ Acute Myeloid Leukemia: A Study from the French Society of Bone Marrow Transplantation and Cell Therapies (2014) (0)
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT (2022) (0)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT (2018) (0)
- Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord (2018) (0)
- Allogeneic Stem Cell Transplantation for t(3;3)(q21;q26)/inv(3)(q21;q26) Acute Myeloid Leukemia - Report from the Acute Leukemia Working Party of the EBMT (2016) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Poor Karnofsky Performance Status. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Impact of Recovery of CD4 and CD8 Lymphocyte Subsets on Acute GVHD after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT). (2005) (0)
- Prevention and Management of Relapse Topic leaders: Peter Bader and Nicolaus Kröger (2019) (0)
- Biological Aspects Topic leaders: Chiara Bonini and Jürgen Kuball (2019) (0)
- Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt) (2018) (0)
- The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising Committee (2018) (0)
- P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma (2022) (0)
- Outcome of Two Loci Mismatched (≤6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study (2019) (0)
- A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2011) (0)
- 6-sulfo LacNAc monocytes are quantitatively and functionally disturbed in systemic sclerosis patients. (2022) (0)
- Specific Organ Complications Topic leaders: Grzegorz Basak and John Snowden (2019) (0)
- Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (2022) (0)
- Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT (2022) (0)
- A415 RIC allo-SCT for Patients with High-Risk Myeloma: A Survey from the SFGM-TC (2009) (0)
- Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1). (2006) (0)
- The Role of Cytogenetic Risk Stratification in FLT3 Mutated NPM1 Negative AML Patients Undergoing Allogeneic Stem Cell Transplantation (alloSCT) in Remission: A Study on Behalf of the ALWP of the EBMT (2021) (0)
- Impact of Gut Mycobiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation (2019) (0)
- Prediction of Leukemia-Free Survival Following Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Thymoglobulin and an unexpected outbreak of Epstein-Barr virus. (2015) (0)
- Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy)- the Role of Donor Kinship: From the ALWP of the EBMT (2021) (0)
- Influence of Cytogenetic, Molecular Abnormalities and Other Risk Factors on the Outcomes of Children with Acute Myelogenous Leukemia Given An Unrelated Cord Blood Transplantation. A Survey on Behalf of Eurocord, ALWP and PDWP of EBMT (2011) (0)
- Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the SFGM-TC. (2019) (0)
- Quantification of the Time and Effort Required For Autologous Peripheral Blood Stem Cell Collection: A European Perspective (2014) (0)
- Donor Lymphocyte Infusions (DLI) for the Treatment of Disease Relapse in Hematological Malignancies Following Allogeneic Transplantation: Similar Efficacy Following RIC or Myeloablative Regimen (2008) (0)
- Impact of chronic graft-versus-host disease (GVHD) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as treatment for acute myeloid leukemia (AML) : a survey from the Acute Leukemia Working Party of the EBMT (2011) (0)
- Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. (2023) (0)
- Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide (DF) for the Treatment of Severe/Very Severe Veno-Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) (2022) (0)
- ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT (2017) (0)
- The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT (2018) (0)
- Indications and Results Topic leaders: Rafael Duarte and Nicolaus Kröger (2019) (0)
- CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES (2019) (0)
- Factors Predicting Allogeneic Peripheral Blood Stem Cell (PBSC) Mobilization After G-CSF Treatment in Healthy Donors (2009) (0)
- A051 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT (2009) (0)
- MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma (2019) (0)
- Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party (2012) (0)
- Age and Disease Status Are Important Risk Factors for Outcome after Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults (2008) (0)
- Reduced Intensity Conditioning Allogeneic Stem cell Transplantation (RIC-alloSCT) for Elderly Acute Myeloid Leukaemia (AML) Patients Over 60 Years: A “donor” Versus “no donor” Comparison (2012) (0)
- Title: Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia (2018) (0)
- Tandem Auto-Allo In Acute Myeloid Leukemia (AML) Patients In First Complete Remission (CR) (2010) (0)
- Allogeneic Stem Cell Tranplantation (allo-SCT) for Adult Patients with Active Refractory/Relapsed Hematological Malignancies: a Survey From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). (2010) (0)
- Achievement of High Concentration of Cyclosporine-a Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Graft (2018) (0)
- Impact of chronic graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (2012) (0)
- Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT (2022) (0)
- Platelets Recovery and Transfusion Needs after Reduced Intensity Conditioning (RIC) Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation (allo-SCT). (2006) (0)
- Better Outcome in Children Compared to AYAs and Young Adults after Allogeneic HSCT for AML: A Multicenter Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM -TC) (2018) (0)
- In 2017, we do not stop progress! (2017) (0)
- Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia (2016) (0)
- A Pooled Analysis of Survival By Defibrotide (DF) Timing of Initiation in Adults with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Following Hematopoietic Stem Cell Transplant (HSCT) (2019) (0)
- P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY (2022) (0)
- Faculty Opinions recommendation of Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? (2008) (0)
- Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT (2011) (0)
- Autologous Stem Cell Transplantation (ASCT) for Patients Aged 60 Years or Older with Classical Hodgkin Lymphoma : A Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) (2014) (0)
- Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy) (2016) (0)
- New Strategy for Allogeneic Peripheral Blood Stem Cell Transplantation After Reduced Intensity Conditioning in Multiple Myeloma: Interim Analysis of the IFM2005-03 Study. (2009) (0)
- Derivation of Prediction Model for Treatment Failure Risk in Multiple Myeloma Patients Based on Biomarkers of Hypercoagulability. The Prospective Observational ROADMAP-MM-CAT Study (2019) (0)
- Autologous Vs Related Vs Unrelated Hematopoietic Stem Cell Transplantation for Adults with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the EBMT (2017) (0)
- Up-front ixazomib in older patients with myeloma. (2021) (0)
- Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas (2014) (0)
- OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis (2022) (0)
- Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies. (2009) (0)
- Impact of Donor Type in Patients with Acute Myeloid Leukemia Given Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Regimen: A Study from the Acute Leukemia Working Party of the EBMT and Eurocord (2017) (0)
- Salvage brentuximab vedotin prior to allogeneic hematopoietic cell transplantation in classical hodgkin lymphoma does not impact survival but reduces the incidence of chronic GVHD: a retrospective study of the EBMT Lymphoma Working Party. (2017) (0)
- PS1411 CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NON-STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE (2019) (0)
- Methodology and Clinical Aspects Topic leaders: Arnon Nagler and Nicolaus Kröger (2019) (0)
- Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study (2022) (0)
- Standard Versus Single Dose-Daily Fractionated Total Body Irradiation Schedules Prior to Allotransplant for Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2017) (0)
- The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organizing Committee (2019) (0)
- Gut microbiome modulates cytokine release syndrome and therapeutic response to CAR-T therapy in hematologic malignancies (2021) (0)
- P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma (2021) (0)
- Multiple myeloma: progresses are made (2016) (0)
- Extracorporeal Photopheresis (ECP) for Acute Graft-Versus Host Disease (GvHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) (2015) (0)
- Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source. (2008) (0)
- Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mohamad Mohty?
Mohamad Mohty is affiliated with the following schools:
